Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data

Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data

BackgroundA significant number of systemic juvenile idiopathic arthritis (sJIA) patients discontinue biologic disease-modifying antirheumatic drugs (bDMARDs) due to lack of efficacy or safety concerns. Studies of biologic therapy switch regimens in sJIA are required.MethodsPatients with sJIA who swi...

Full description

Bibliographic Details
Main Authors: Ekaterina Alexeeva, Elizaveta Krekhova, Tatyana Dvoryakovskaya, Ksenia Isaeva, Aleksandra Chomakhidze, Evgeniya Chistyakova, Olga Lomakina, Rina Denisova, Anna Mamutova, Anna Fetisova, Marina Gautier, Dariya Vankova, Ivan Kriulin, Ruslan Saygitov
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Pediatrics
Subjects:
systemic juvenile idiopathic arthritis
tocilizumab
canakinumab
second-line biologic
switching
Online Access:https://www.frontiersin.org/articles/10.3389/fped.2023.1114207/full

Internet

https://www.frontiersin.org/articles/10.3389/fped.2023.1114207/full

Similar Items